$ACAD
ACADIA PHARMACEUTICALS INC

2023 Q2 Form 10-Q Financial Statement

#000095017023018927 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $165.2M $118.5M $115.5M
YoY Change 22.79% 2.59% 8.37%
Cost Of Revenue $7.459M $1.667M $2.950M
YoY Change 179.68% -43.49% 35.01%
Gross Profit $157.8M $116.8M $112.5M
YoY Change 19.62% 3.8% 7.81%
Gross Profit Margin 95.49% 98.59% 97.45%
Selling, General & Admin $95.97M $101.2M $96.68M
YoY Change 6.75% 4.71% -13.42%
% of Gross Profit 60.83% 86.68% 85.92%
Research & Development $58.77M $69.14M $128.9M
YoY Change -22.31% -46.34% 126.17%
% of Gross Profit 37.25% 59.2% 114.52%
Depreciation & Amortization $1.766M $426.0K $516.0K
YoY Change 242.91% -17.44% -1.71%
% of Gross Profit 1.12% 0.36% 0.46%
Operating Expenses $154.7M $170.4M $225.5M
YoY Change -6.53% -24.46% 33.74%
Operating Profit $3.037M -$53.58M -$113.0M
YoY Change -109.02% -52.59% 69.26%
Interest Expense $4.550M $3.800M $105.0K
YoY Change 684.48% 3519.05% -47.5%
% of Operating Profit 149.82%
Other Income/Expense, Net -$1.244M $4.845M $340.0K
YoY Change 150.3% 1325.0% -334.48%
Pretax Income $6.343M -$44.90M -$112.6M
YoY Change -118.9% -60.11% 69.47%
Income Tax $5.229M -$1.900M $485.0K
% Of Pretax Income 82.44%
Net Earnings $1.114M -$43.02M -$113.1M
YoY Change -103.28% -61.95% 70.14%
Net Earnings / Revenue 0.67% -36.32% -97.91%
Basic Earnings Per Share $0.01 -$0.27 -$0.70
Diluted Earnings Per Share $0.01 -$0.27 -$701.2K
COMMON SHARES
Basic Shares Outstanding 162.6M 162.2M 161.2M
Diluted Shares Outstanding 165.0K 162.3M 161.2M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $375.4M $402.9M $446.0M
YoY Change -13.97% -9.67% -22.81%
Cash & Equivalents $107.9M $290.9M $204.9M
Short-Term Investments $267.4M $112.0M $241.1M
Other Short-Term Assets $23.90M $23.63M $25.76M
YoY Change 14.05% -8.24% -9.63%
Inventory $9.199M $11.02M $13.21M
Prepaid Expenses $23.90M $23.63M $25.76M
Receivables $81.85M $65.92M $62.71M
Other Receivables $2.304M $4.335M $769.0K
Total Short-Term Assets $492.6M $502.9M $542.2M
YoY Change -7.49% -7.26% -19.55%
LONG-TERM ASSETS
Property, Plant & Equipment $57.58M $5.595M $7.531M
YoY Change 720.62% -25.71% -89.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $24.35M $12.43M $4.336M
YoY Change 534.2% 186.72% -42.95%
Total Long-Term Assets $150.1M $152.5M $82.03M
YoY Change 87.1% 85.86% 1.02%
TOTAL ASSETS
Total Short-Term Assets $492.6M $502.9M $542.2M
Total Long-Term Assets $150.1M $152.5M $82.03M
Total Assets $642.8M $655.3M $624.3M
YoY Change 4.9% 4.97% -17.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.81M $17.42M $10.77M
YoY Change 58.69% 61.79% 22.36%
Accrued Expenses $169.1M $206.9M $108.8M
YoY Change 59.82% 90.08% 8.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $187.9M $224.3M $119.6M
YoY Change 59.7% 87.54% 9.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $59.03M $5.305M $4.373M
YoY Change 964.83% 21.31% -93.19%
Total Long-Term Liabilities $59.03M $5.305M $4.373M
YoY Change 964.83% 21.31% -93.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $187.9M $224.3M $119.6M
Total Long-Term Liabilities $59.03M $5.305M $4.373M
Total Liabilities $247.0M $281.0M $179.5M
YoY Change 38.81% 56.61% 3.37%
SHAREHOLDERS EQUITY
Retained Earnings -$2.411B -$2.413B -$2.267B
YoY Change 4.82% 6.44%
Common Stock $2.808B $2.787B $2.712B
YoY Change 2.61% 2.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $395.8M $374.3M $444.8M
YoY Change
Total Liabilities & Shareholders Equity $642.8M $655.3M $624.3M
YoY Change 4.9% 4.97% -17.34%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $1.114M -$43.02M -$113.1M
YoY Change -103.28% -61.95% 70.14%
Depreciation, Depletion And Amortization $1.766M $426.0K $516.0K
YoY Change 242.91% -17.44% -1.71%
Cash From Operating Activities $8.201M -$17.93M -$76.33M
YoY Change -162.48% -76.51% 26.9%
INVESTING ACTIVITIES
Capital Expenditures $40.00M $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$154.3M $192.5M $131.3M
YoY Change 176.51% 46.57% 311.1%
Cash From Investing Activities -$194.3M $192.5M $131.3M
YoY Change 248.2% 46.57% 325.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.467M
YoY Change -68.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.478M 1.466M 2.467M
YoY Change 42.99% -40.58% -68.07%
NET CHANGE
Cash From Operating Activities 8.201M -17.93M -76.33M
Cash From Investing Activities -194.3M 192.5M 131.3M
Cash From Financing Activities 5.478M 1.466M 2.467M
Net Change In Cash -180.6M 176.0M 57.49M
YoY Change 177.46% 206.25% -366.86%
FREE CASH FLOW
Cash From Operating Activities $8.201M -$17.93M -$76.33M
Capital Expenditures $40.00M $0.00
Free Cash Flow -$31.80M -$76.33M
YoY Change 142.28% 24.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-50768
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
06-1376651
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12830 El Camino Real
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2023Q1 dei City Area Code
CityAreaCode
858
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
558-2871
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ACAD
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
162625379
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
290895000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114846000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
111978000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
301977000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
65915000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
62195000
CY2023Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
4335000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
885000
CY2023Q1 acad Short Term Inventory
ShortTermInventory
6095000
CY2022Q4 acad Short Term Inventory
ShortTermInventory
6636000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23632000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
21398000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
502850000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
507937000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5595000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6021000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54151000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55573000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
69583000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2023Q1 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4924000
CY2022Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4924000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12432000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7587000
CY2023Q1 us-gaap Assets
Assets
655305000
CY2022Q4 us-gaap Assets
Assets
587812000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
17422000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12746000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
206879000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
112884000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
224301000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
125630000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51441000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52695000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5305000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9074000
CY2023Q1 us-gaap Liabilities
Liabilities
281047000
CY2022Q4 us-gaap Liabilities
Liabilities
187399000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162384178
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
162384178
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162064872
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
162064872
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2787034000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2770923000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2412572000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2369551000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-220000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-975000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
374258000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
400413000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
655305000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
587812000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
118462000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115468000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
118462000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
115468000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1667000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2950000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69144000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
128855000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
101235000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
96679000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
172046000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
228484000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-53584000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-113016000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3800000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
105000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4845000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
340000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44939000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112571000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1918000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
485000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43021000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-113056000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162263000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
162263000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161231000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161231000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43021000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-113056000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
757000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-422000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42266000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113476000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-43021000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-113056000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14705000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14963000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2267000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-447000
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
4845000
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
339000
CY2023Q1 acad Loss On Sale Of Investment Securitie
LossOnSaleOfInvestmentSecuritie
505000
CY2022Q1 acad Loss On Sale Of Investment Securitie
LossOnSaleOfInvestmentSecuritie
0
CY2023Q1 us-gaap Depreciation
Depreciation
426000
CY2022Q1 us-gaap Depreciation
Depreciation
516000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3720000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1653000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
3450000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-209000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-481000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-833000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2234000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1863000
CY2023Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1726000
CY2022Q1 acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-1522000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4676000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3892000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
24510000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
19672000
CY2023Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1656000
CY2022Q1 acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2117000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3769000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2661000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17933000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76329000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
66892000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
259410000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
131345000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
192518000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
131345000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1466000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2467000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1466000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2467000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
176049000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
57485000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120616000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153205000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
296665000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210690000
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
69583000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
400413000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
540894000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
374258000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
444797000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114846000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
290895000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147435000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204920000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
120616000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
296665000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153205000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210690000
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q1 us-gaap Inventory Net
InventoryNet
11019000
CY2022Q4 us-gaap Inventory Net
InventoryNet
11560000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1037000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
230174000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1037000
CY2023Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
183000000.0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20764000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17540000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14705000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14963000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1594000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1926000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4251000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4427000
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5174000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5207000
CY2023Q1 us-gaap Inventory Net
InventoryNet
11019000
CY2022Q4 us-gaap Inventory Net
InventoryNet
11560000
CY2023Q1 acad Short Term Inventory
ShortTermInventory
6095000
CY2022Q4 acad Short Term Inventory
ShortTermInventory
6636000
CY2023Q1 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4924000
CY2022Q4 us-gaap Inventory For Long Term Contracts Or Programs
InventoryForLongTermContractsOrPrograms
4924000
CY2023Q1 acad Accrued Milestone And Contingent Payments
AccruedMilestoneAndContingentPayments
69583000
CY2022Q4 acad Accrued Milestone And Contingent Payments
AccruedMilestoneAndContingentPayments
0
CY2023Q1 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
50137000
CY2022Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
26046000
CY2023Q1 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
33656000
CY2022Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
35048000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21192000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28023000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
12876000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
11377000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9173000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9305000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10262000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3085000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
206879000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
112884000
CY2023Q1 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
112212000
CY2023Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
27000
CY2023Q1 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
261000
CY2023Q1 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
111978000
CY2022Q4 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
302968000
CY2022Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
46000
CY2022Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
1037000
CY2022Q4 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
301977000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
17
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
43
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
95142000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
261000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
95142000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
261000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
230174000
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
500000
CY2023Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
411117000
CY2023Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
30830000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
395597000
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
898000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
898000
CY2023Q1 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Vesting Of Awards
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVestingOfAwards
169000
CY2023Q1 acad Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Expense Forfeited
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExpenseForfeited
-19000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
199000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1247000
CY2021Q4 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
15100000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
4400000
CY2023Q1 us-gaap Deferred Compensation Arrangement With Individual Cash Award Granted Amount
DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount
11600000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
2100000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
300000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
900000
CY2023Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 0.8 years to 8.2 years, some of which include options to extend for up to two five-year terms.
CY2023Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
some of which include options to extend for up to two five-year terms.
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2181000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2110000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10801000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
60614000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.044
CY2020Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
40300000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2370000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2190000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
304000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1440000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9173000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9305000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
51441000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52695000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
60614000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
62000000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7127000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9228000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9308000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8672000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8389000
CY2023Q1 acad Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
28691000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
71415000
CY2021Q1 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
19200000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1900000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44900000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
500000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112600000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.043
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.004
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
acad-20230331_cal.xml Edgar Link unprocessable
acad-20230331_lab.xml Edgar Link unprocessable
0000950170-23-018927-index-headers.html Edgar Link pending
0000950170-23-018927-index.html Edgar Link pending
0000950170-23-018927.txt Edgar Link pending
0000950170-23-018927-xbrl.zip Edgar Link pending
acad-20230331.htm Edgar Link pending
acad-20230331.xsd Edgar Link pending
acad-ex31_1.htm Edgar Link pending
acad-ex31_2.htm Edgar Link pending
acad-ex32_1.htm Edgar Link pending
acad-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
acad-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acad-20230331_pre.xml Edgar Link unprocessable
acad-20230331_htm.xml Edgar Link completed
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending